Background and aims: Causes of inflammatory bowel diseases are not well understood and the most prominent forms, Crohn's disease (CD) and ulcerative colitis (UC), are sometimes hard to distinguish. Glycosylation of IgG has been associated with CD and UC. IgG Fc glycosylation affects IgG effector functions. We evaluated changes in IgG Fc glycosylation associated with UC and CD, as well as with disease characteristics in different patient groups.
Methods: We analyzed 3441 plasma samples obtained from 2 independent cohorts of patients with CD (874 patients from Italy and 391 from the United States (US)) or UC (1056 from Italy and 253 from the US and healthy individuals [controls] ; 427 from Italy and 440 from the US). IgG Fc glycosylation (tryptic glycopeptides) was analyzed by liquid chromatography coupled to mass spectrometry. We analyzed associations between disease status (UC vs controls, CD vs controls, and UC vs CD) and glycopeptide traits, and associations between clinical characteristics and glycopeptide traits, using a logistic regression model with age and sex included as covariates.
Results: Patients with CD or UC had lower levels of IgG galactosylation than controls. For example, the odds ratio (OR) for IgG1 galactosylation in patients with CD was 0.59 (95% confidence interval [CI] , 0.51-0.69) and for patients with UC was 0.81 (95% CI, 0.71-0.92). Fucosylation of IgG was increased in patients with CD vs controls (for IgG1: OR, 1.27; 95% CI, 1.12-1.44), but decreased in patients with UC vs controls (for IgG23: OR, 0.72; 95% CI, 0.63-0.82). Decreased galactosylation associated with more severe CD or UC, including the need for surgery in patients with UC vs controls (for IgG1: OR, 0.69; 95% CI, 0.54-0.89) and in patients with CD vs controls (for IgG23: OR, 0.78; 95% CI, 0.66-0.91).
Conclusions: In a retrospective analysis of plasma samples from patients with CD or UC, we associated levels of IgG Fc glycosylation with disease (compared to controls) and its clinical features. These findings could increase our understanding of mechanisms of CD and UC pathogenesis and be used to develop diagnostics or guide treatment.
Introduction
The incidence of inflammatory bowel diseases (IBDs) is increasing [233] , and currently affects approximately 1 in 200 people in developed countries [234] . In Europe, IBD has a prevalence of 2.5 to 3 million people [235, 236] , with health care costs of €4.6 to 5.2 billion per year [235] , while in the United States, the costs for IBD are estimated at US$11-28 billion per year [237] . The two main types of IBD are Crohn's disease (CD) and ulcerative colitis (UC), which are further subcategorized by the Montreal classification, based on age of onset, disease location, and behavior (CD), and on disease extent and severity (UC) [238] .
IBD results from an aberrant host immune response to luminal gut microbiota occurring in genetically susceptible individuals [239] . However, genetic variants associated with IBD explain only 7.5% and 13.6% of UC and CD susceptibility [240] , respectively, indicating the importance of studying other factors that contribute to the course of IBD. One of these factors is the regulation of innate and adaptive immunity.
The majority of extracellular and membrane proteins are glycosylated, and glycans are directly involved in the pathophysiology of every major disease [241, 242] . Alternative glycosylation affects the protein structure and its function in a similar manner to mutations in the amino acid sequence [243] . Protein glycosylation has been reported to change significantly in various diseases [96, 103, 244, 245] , including cancer [246] and IBD [247] [248] [249] . Current strategies for diagnosis, prognosis, and monitoring of IBD are often invasive or lack adequate sensitivity [250, 251] , therefore, the measurement of protein glycosylation in serum could be an attractive, minimally invasive biomarker and assist patient stratification for precision medicine.
Recent studies have shown that IgG, which is a key effector of the humoral immune system and has multiple roles in balancing inflammation on the systemic level [252] , has altered glycosylation in a number of different diseases [253], including IBD [95, 248, 249] . Additionally, genome-wide association studies of IgG glycosylation have shown pleiotropy with IBD susceptibility loci, suggesting a role for IgG glycosylation in the onset and progression of IBD [240, 254, 255] . However, none of these studies have elucidated the mechanisms behind the observed changes or their clinical relevance.
IgG molecules contain 2 diantennary N-glycans covalently attached to conserved Nglycosylation sites at Asn-297 on each of its heavy chains. The most complex Fc glycan, FA2BG2S2, is a diantennary (A2) digalactosylated (G2) and disialylated structure with a bisecting b(1,4) N-acetylglucosamine (GlcNAc) (B) and an α(1,6) fucose (F) attached to core GlcNAc (Figure 6 .1) [105, 177] . Other IgG glycans correspond to this complex structure with the lack of one or more sugar units. Fc glycosylation of IgG is complex and affected by multiple genetic [255] , epigenetic [256] , and environmental factors [74] , resulting in a glycome composition that is very variable between individuals, but stable within an individual in homeostatic conditions [225] . Age is a notable exception that strongly affects the composition of the IgG glycome of an individual [81] . IgG in mice can have pro-and anti-inflammatory activity, depending on its glycosylation status. Sialylation of murine IgG is associated with anti-inflammatory activity [202] , while IgG core fucosylation limits IgG-mediated antibody-dependent cellular cytotoxicity (ADCC) [74, 257] and activates complement [258] . Decreased galactosylation of IgG is reported in inflammatory diseases, suggesting an anti-inflammatory role of the attached galactoses [95] . However, pro-inflammatory effects of IgG galactosylation have also been observed [52, 259] , hinting at alternative interpretations. The composition of the N-glycan attached to the Fc region of IgG affects binding of IgG to both high-and low-affinity Fc gamma receptors [51, 243] . Although the exact molecular mechanism is still elusive [260] , the glycans attached to IgG strongly affect immunosuppressive properties of IgG, as exemplified in therapeutic function of intravenously administered immunoglobulins [261] . Inter-individual variability in IgG glycome composition and its changes in disease thus have profound effects on the immune system. The understanding of functional significance of glycosylation changes in disease are complicated by subclass-specific effects, as demonstrated in different models [36] . Until recently, the IgG glycome in IBD was analyzed on the level of total released glycans [95] by ultraperformance liquid chromatography, which does not discriminate between individual IgG subclasses nor glycan location. Fc and Fab glycosylation of IgG differ significantly and we also demonstrated that disease course can specifically associate with Fc glycosylation [262] . In this study, we used liquid chromatography coupled to mass spectrometry (LC-MS), that enables high-throughput analysis of IgG Fc glycans in a subclass-specific manner [85, 197] and provides a more detailed insight into IgG glycosylation changes in IBD. By measuring subclass-specific IgG Fc N-glycosylation in 3441 IBD patients and controls from two independent cohorts participating in the IBD-BIOM (Inflammatory Bowel Disease Biomarkers) Consortium project, we demonstrated a clear difference in IgG Fc glycosylation between diseased and healthy individuals, but also between the different forms of IBD, and associations with disease severity.
Materials and Methods

Clinical Samples and Ethical Considerations
Samples were collected from two case-control populations, the Italian cohort (ITA) from Italy (n = 2357) and the US cohort from the United States (n = 1084), each including CD (ITA: n = 874, US: n = 391) and UC (ITA: n = 1056, US: n = 253) patients as well as healthy controls (HC) (ITA: n = 427, US: n = 440). Both cohorts were collected with the approval of the local ethics committees and informed consent was obtained from all participants. Phenotype was defined using the Montreal classification at the last follow-up [238] . Clinical characteristics were obtained by chart review according to criteria agreed by the clinicians and as described previously [263] [264] [265] (Table 6 .1).
Sample Preparation and Data Preprocessing
Sample preparation and glycopeptide analysis (IgG purification by Protein G affinity chromatography, tryptic digestion, nano-LC-MS analysis, and data preprocessing) were performed separately for the ITA and US cohort [28, 74, 85, 197, 198] Figure 1) . The tryptic Fc glycopeptides for IgG2 and 3 have identical peptide moieties in the Caucasian population and are therefore not distinguishable with our methods [163, 266] . Annotation of the spectra was done based on accurate mass and literature [74, 256] . Using the directly measured glycopeptides, derived glycosylation traits were calculated per IgG subclass (Supplementary Tables 2 and 3), which average particular glycosylation features like galactosylation, fucosylation, sialylation, and the presence of a bisecting GlcNAc (bisection).
Statistical Analysis
Data analysis and visualization was performed with R v3.0.1 (R Foundation for Statistical Computing, Vienna, Austria). Association analyses between disease status (UC patients and HC, CD patients and HC and UC and CD patients) and glycopeptide traits as well as within-disease analyses of associations between clinical characteristics and glycopeptide traits were performed using a logistic regression model with age and sex included as additional covariates. For UC, we assessed disease location, duration of the disease, and need for a colectomy. Regarding disease location, we analyzed the differences between Montreal E1 (proctitis) and E2 (left-sided UC) against E3 (extensive UC). For CD, we assessed disease location and behavior, duration of disease, and the need for surgery. For CD behavior, we compared Montreal B2 (stricturing) and B3 (internal penetrating) with B1 (inflammatory disease). For location, we compared Montreal L1 (ileal) against L2 (colonic disease) and L1 against L3 (ileocolonic disease). For both diseases, we used a cutoff of 5 years since diagnosis to stratify disease duration into two groups. In the ITA cohort, for CD as well as for UC, patients treated with the third most potent medication (steroids) were compared to patients treated with mesalazine only and, in addition, patients treated with the first most potent medication (inhibitor of tumor necrosis factor [anti-TNF]) were compared to patients treated with the second most potent medication (azathioprine [AZ] and 6-mercaptopurine [6MP]). These latter tests were also done in the US cohort. Both case-control and within-disease analyses were first performed for each cohort separately and then combined using an inverse variance-weighted meta-analysis approach (R package "metafor" [267] ). The false discovery rate was controlled for each analysis using the Benjamini-Hochberg method with false discovery rate set to 0.05. All P values were corrected for multiple testing.
For prediction of disease status, a regularized logistic (elastic net) regression model was applied (R package "glmnet" [268]) using direct glycosylation traits as predictors (Supplementary Materials and Methods). Three models were built for each cohort (UC vs HC, CD vs HC, and UC vs CD), using age, sex, and glycopeptide measurements as predictors. To evaluate the performance of the predictive models based on the individual glycoforms, a 10-cross-validation procedure was used. The predictions from each validation round were merged into 1 validation set on which the performance of each model was evaluated based on the area under the curve (AUC) criteria.
Results
IgG Fc Glycosylation Differences Between Inflammatory Bowel Disease Patients and Healthy Controls
For both CD and UC, we observed an increase in agalactosylated IgG glycopeptides in both cohorts compared to HC and a corresponding decrease of monogalactosylated (not significant for IgG1 in CD patients of the US cohort, but significant in meta-analysis of both cohorts) and digalactosylated IgG glycopeptides (not significant for IgG1 and IgG4 in UC patients of the ITA cohort, but significant in metaanalysis of both cohorts) ( Table 6 .2, Supplementary Table 3 . b To assess differences between HC and UC patients (HC = 0, UC = 1), HC and CD patients (HC = 0, CD = 1), and UC and CD patients (UC = 0, CD = 1), logistic regression was performed using age and sex as co-variables. c P values are indicated in bold when statistically significant after multiple testing correction (5% false discover rate Supplementary Tables 5-7, Figure 6 .2). In both cohorts, all IgG subclasses showed lower overall galactosylation (A2G) for CD patients compared to UC patients. A decrease in sialylation was also associated with CD in both the US and the ITA cohort, but for UC this effect was only seen in the US cohort. Sialylation per galactose of diantennary glycans (A2GS) increased with disease, or did not change at all. We observed a subclass and disease-specific association for fucosylated IgG glycopeptides (A2F). Increased A2F was associated with CD in the US cohort for both IgG1 and IgG23 and for IgG1 in ITA cohort. Conversely, there was a negative association between IgG23 A2F and UC in both cohorts. Furthermore, both cohorts showed IgG1 and IgG23 A2F to be high in CD patients compared to UC patients. IgG4 bisection (structures with bisecting β(1,4) Nacetylglucosamine on IgG4) was low for CD and UC compared to HC in both cohorts. A decrease in bisection (A2B) was also observed for the other IgG subclasses in UC patients of the ITA cohort, on the other hand, IgG1 and IgG23 A2B was increased for CD compared to HC in the US cohort. For both cohorts IgG1 and IgG23 A2B was higher in CD compared to UC. Results for the individual IgG glycoforms are shown in Supplementary Tables 8-11 , and Supplementary Figure 2.
Discrimination of Disease Status
The discriminatory performance of individual glycoforms per IgG subclass in distinguishing UC from HC, CD from HC, and UC from CD, was evaluated for ITA and US cohorts separately, using a regularized logistic regression model. The receiver operating characteristic curves for the ITA cohort showed a good performance in discriminating UC from HC (AUC = 0.801; To assess which glycoforms were most important in these models, individual receiver operating characteristic analyses were performed per glycoform per IgG subclass, revealing for example G1 on IgG23 to be in the top 5 of most important glycoforms discriminating UC from HC in both cohorts (Supplementary Figures 3A and 4A) . In addition, IgG23 and IgG4 G0F were in the top 5 between CD and HC in both cohorts (Supplementary Figures 5A and 6A ) and IgG23 G0F, G0FN, G2, and G2F were found in both cohorts to be in the top 5 most discriminating glycans between UC and CD (Supplementary Figures 7A and 8A) . These findings were also reflected in the predictive values of the individual-derived traits (Supplementary Figures   3-8, panels B) . Supplementary Table 8 . Analysis of the differences in glycan traits between UC and HC, CD and HC, and UC and CD, were performed using a logistic regression model with age and sex included as additional covariates (Table 6.2, Supplementary Tables 5-7) .
Disease Behavior, Location, and Classification
In the ITA cohort (and the meta-analysis of both cohorts) an increase in agalactosylated IgG glycopeptides and a decrease in digalactosylated IgG glycopeptides were associated with extensive UC and the need for surgery in UC. In addition, the need for surgery was associated with less sialylated glycans on all IgG subclasses. In both cohorts, agalactosylated IgG1 glycopeptides decreased and monogalactosylated IgG1 glycopeptides increased with the duration of UC (Supplementary Table 12 and Figure 6 .4). In addition, for surgery in CD patients, the IgG23 agalactosylation increased in both cohorts, while IgG23 digalactosylation was decreased. Furthermore, IgG23 sialylation decreased in the ITA cohort (and the meta-analysis of both cohorts). Also a worse disease behavior Supplementary Table  8 . Analysis of the association between derived glycan traits and clinical characteristics in UC were performed using a logistic regression model, with age and sex included as additional covariates, statistically significant findings are indicated with an asterisk (*) (Supplementary Table 12) . Supplementary   Table 8 . Analysis of the association between derived glycan traits and clinical characteristics in CD were performed using a logistic regression model, with age and sex included as additional covariates, statistically significant findings are indicated with an asterisk (*) (Supplementary Table   13 ).
Use of Medication
For UC patients in the ITA cohort, an increase in overall agalactosylation was associated with the use of steroids compared to mesalazine. This difference was not observed for CD patients in the ITA cohort (Supplementary Tables 16 and 17) . In the US cohort, UC patients treated with anti-TNF showed a decrease in overall galactosylation, and IgG1 and IgG4 sialylation when compared to patients treated with AZA/6MP. This was not replicated in the ITA cohort. However, the same observation was made for CD patients in the US cohort (and the meta-analysis of both cohorts), where a decrease in overall galactosylation was associated with treatment with anti-TNF compared to treatment with AZA/6MP. Results for the individual IgG glycoforms are shown in Supplementary Tables 18 and 19.
Discussion
In this study, we analyzed subclass-specific IgG Fc glycosylation in IBD in two independent cohorts, using a nano-LC-MS method [85] . The importance of altered glycosylation in IBD has been reported before in different models [247, 269] and specifically IgG Fc glycosylation was found to play an important role in a number of inflammatory processes [270] , including the course of IBD [95] .
Associations Between IgG Fc glycosylation and Inflammatory Bowel Disease
Although observed for both diseases, associations between galactosylation and sialylation and disease were consistently more pronounced in CD than in UC. IgG Fc galactosylation was decreased in IBD patients compared to HC. This decrease was previously found in the total IgG N-glycome [95], and we revealed that this change is not subclass-specific (Figure   6 .2). Decreased IgG Fc galactosylation has been reported in different inflammatory diseases [95] . Because IgG galactosylation has been shown to also decrease with aging [256] , observed changes in galactosylation are most likely connected to inflammation in general and are not IBD-specific. On the other hand, decreased galactosylation on antigenspecific antibodies in rheumatoid arthritis precedes onset of the disease [93, 271] , which indicates that the individual differences in IgG galactosylation could be associated with predisposing factors for the development of inflammatory disease, including IBD [272] .
In addition, sialylation was decreased in IBD, which was previously observed in CD but not UC [95] . This effect was less pronounced than the galactosylation effect and it was also not replicated in both cohorts for all IgG subclasses. Likely, the decrease in sialylation is a by-effect of the observed decrease in galactosylation, as galactosylation is required for the addition of a sialic acid to a glycan. This is supported by our observation that sialylation per galactose (derived trait A2GS) did not show a difference between either CD or UC and HC, or increased with disease. Various studies in humans have shown the predominant role of galactosylation rather than sialylation in the regulation of pro-and antiinflammatory effects of IgG [52, 54, 97] .
Recently, it was discovered that 5 genetic loci associated with IgG glycosylation showed pleiotropy with IBD, suggesting the role of IgG glycosylation in the development and course of IBD [240, 254, 255] . Mutations in these genetic loci associated with IgG galactosylation, fucosylation, and bisection, features also significantly changing with IBD as found in the current study. As multiple-derived glycosylation traits were associated with IBD, we hypothesized that IgG Fc glycosylation might be used as tool to discriminate between IBD patients and HC. Our prediction models were based on the individual glycoforms per IgG subclass and showed an improved discriminatory performance compared to previously published models based on individual glycoforms [95] , this is likely due to the higher number of individual glycoforms included in our model and the subclass specificity of our analysis. For example, in both cohorts, IgG23 and IgG4 glycoforms showed the largest effect size between HC and IBD patients. IgG23 and IgG4 are less abundant in human plasma than IgG1 [191] , likely causing the effect of their glycoforms to be partly masked during released glycan analysis. Despite the differences between the two cohorts in terms of disease behavior in CD and disease extent in UC (both more severe in the US cohort, likely due to a longer disease duration) and collection of the samples (a single tertiary/quartenary IBD center for the US cohort and multiple primary centers for the ITA cohort), we still found equally performing models for both of them.
These findings suggest possible clinical utility of glycans as minimally invasive diagnostic markers. However, future studies confirming these findings and contrasting/combining these markers with others minimally invasive prognostic markers are warranted [273] [274] [275] . Previous studies have identified IBD-associated serologies, transcriptomics, and genetics. Especially the comparative utility of IgG Fc glycosylation as peripheral biomarker compared to IBD-associated serologies, which measure antibodies to commensal flora (eg, ASCA, anti-CBIR1, and ANCA) [264, 273, 276, 277] , should be evaluated. The preferred study design for this would be a prospective longitudinal study that further explores the impact of changes in disease severity and progression over time. Previously, it was suggested that the IgG glycome of healthy individuals is stable over time [90] , although influenced by changes in lifestyle and environmental factors [90] . In the context of IBD, it is likely to change with disease activity.
Differences Between Crohn's Disease and Ulcerative Colitis
Reliable differentiation between UC and CD is currently done by colonoscopy (invasive) or radiology (radiation exposure) [278] . Current methods based on serology markers, like antibodies specific for microbial antigens, still do not reach the specificity and sensitivity demanded for a diagnostic test [279] . In addition, the differences in mechanisms leading to the development of these diseases remain unclear [280] . Lower IgG galactosylation was more pronounced in CD than in UC, which might indicate a more severe inflammatory response in CD [186] . Fucosylation was decreased in UC, but increased in CD, suggesting different regulation mechanisms. The absence of a fucose on an IgG Fc glycan has shown to improve Fc binding to Fcg receptor III, thereby enhancing ADCC [47] . As an increased galactosylation also enhances the ADCC activity of antibodies in in vitro models, the combination of a lower fucosylation and higher galactosylation in UC compared to CD might result in higher ADCC activity in UC than in CD [259] . IgG Fc bisection was also different between UC and CD patients, showing a higher bisection in CD than in UC. This was consistent with the previous observation that IgG bisection was higher in CD, but not in UC, compared to HC [95] . Although bisection has a large influence on the structure of a glycan, its effect on antibody function is largely unknown [74] . Various studies report an increased bisection to be related to a higher antibody affinity for Fcg receptor III and, therefore, an associated increase of ADCC [62, 281] .
Associations Between IgG Fc Glycosylation and Disease Status
The potential role of IgG Fc glycosylation in the course and development of IBD has been consolidated through confirming, for the first time, the changes in IgG Fc glycosylation with clinical subphenotypes of UC and CD. The increase of aglycosylated glycoforms with more severe disease and the need for surgery in both UC and CD might suggest that when the disease involves more of the colon (more extensive [E3] UC or ileocolonic [L3] CD) and is more severe (there is a need for surgery), IgG has less possibilities to suppress the inflammation [89] . With longer duration of UC, on the other hand, a decrease in agalactosylation was observed, which was not detected with duration in CD. This can be connected to the different disease behaviors, as for UC, it is known that disease activity can decrease over time, while CD usually has a pattern of worsening activity [282] .
The treatment exposures in the two cohorts were different, IBD patients in the US cohort had all been exposed to corticosteroids, which was not the case in the ITA cohort, where the patients on and off corticosteroids were compared. In both cohorts, patients on anti-TNF therapy (more severe cases) were compared to the ones exposed to AZA/6MP (less severe cases) [283, 284] . In the US cohort, we observed increased agalactosylation for all subclasses in IBD patients on anti-TNF therapy compared to patients on AZA/6MP. This was not replicated in the ITA cohort, which likely reflects the heterogeneity of the two cohorts in terms of treatment guidelines. However, in the ITA cohort, an increase in agalactosylated structures was found with the use of corticosteroids as most potent treatment, compared to the less potent one with mesalazine. Steroids compared to mesalazine and anti-TNF compared to AZA/6MP might be considered surrogate markers for disease severity, as they are used when the disease progresses [283, 284] . This corresponds to our findings that more severe disease was also associated with a decrease in IgG Fc galactosylation. Although corticosteroids have an anti-inflammatory effect [285] , our findings suggest that the observed glycosidic changes are not an effect of therapy, but are rather connected to a more severe disease.
Conclusions
In this study, we confirmed previous associations of reduced galactosylation in IBD compared to HC. In addition, it was demonstrated that this same glycosylation trait was associated with more extensive and progressive disease, suggesting a potential role of IgG Fc glycosylation as diagnostic and/or prognostic tool. Furthermore, we found the IgG glycosylation features fucosylation, galactosylation, and bisection to be different between UC and CD patients. Individual glycoforms showed good performance for distinguishing both UC and CD from HCs and fair performance for distinguishing UC from CD, which gave an insight into the difference in mechanisms behind the two diseases. The reported differences in IgG Fc glycans might influence the development and behavior of IBD through affecting binding of IgG to FcgRs [51, 243] . Furthermore, individual differences in IgG glycosylation might affect efficacy of therapeutic monoclonal antibodies, which have to compete with circulating IgG to activate effector functions [286] . The reported changes in IgG Fc glycosylation in the current study give guidelines for future, prospective studies that should elucidate the longitudinal relationship between changes in IgG Fc glycans and development of disease, and disease progression, as well as their role in predicting treatment response. Clinical exploitation of these glycan markers will be facilitated by the existing broad application in clinical laboratories of mass spectrometry or capillary electrophoresis, which show great potential for glycomics assays [287, 288] .
